Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3199732 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2LTA4HHRH3CHRNB2CHRNB4 | |
| SCHEMBL27961063 | 0.97 | SMN1; SMN2 (0.35) | SMN1; SMN2LTA4HHRH3CHRNB2CHRNB4 | |
| SCHEMBL19837632 | 0.97 | SMN1; SMN2 (0.35) | SMN1; SMN2LTA4HHRH3CHRNB2CHRNB4 | |
| SCHEMBL446258 | 0.97 | — | — | |
| SCHEMBL4962729 | 0.97 | — | — | |
| SCHEMBL9112203 | 0.83 | SIGMAR1 (0.41) | LTA4HHRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9112196 | 0.83 | SIGMAR1 (0.41) | LTA4HHRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL23872301 | 0.83 | HRH3 (0.43) | SMN1; SMN2LTA4HHRH3CHRNB2CHRNB4 | |
| SCHEMBL10748748 | 0.83 | HRH3 (0.43) | SMN1; SMN2LTA4HHRH3CHRNB2CHRNB4 | |
| SCHEMBL7227482 | 0.83 | HRH3 (0.43) | SMN1; SMN2LTA4HHRH3CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101203494-A | Process for the synthesis of substituted 3-cyanoquinolines and intermediates thereof | WYETH CORP (US) | 2008-06-18 | — | — | CN | claimed |
| EP-1883631-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | Wyeth (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2006127207-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | WYETH (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | WYETH (US) | 2006-11-30 | — | — | US | claimed |
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| EP-1599482-A4 | PYRAZOLO 1,5-A PYRIMIDINE DERIVATIVES | TEIJIN PHARMA LTD (JP) | 2008-10-01 | — | — | EP | disclosed |
| CN-101203494-A | Process for the synthesis of substituted 3-cyanoquinolines and intermediates thereof | WYETH CORP (US) | 2008-06-18 | — | — | CN | disclosed |
| EP-1883631-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | Wyeth (US) | 2008-02-06 | — | — | EP | disclosed |
| CN-101039945-A | Pyrazolo [1, 5-a ] pyrimidine derivatives | TEIJIN PHARMA LTD (JP) | 2007-09-19 | — | — | CN | disclosed |
| EP-1780212-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006127207-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
| US-20060189632-A1 | Pyrazolo[1,5-A] pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | TEIJIN PHARMA LIMITED | 2006-06-22 | — | — | US | disclosed |
| EP-1599482-A1 | PYRAZOLO 1,5-A PYRIMIDINE DERIVATIVES | Teijin Pharma Limited (JP) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076458-A1 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | TEIJIN PHARMA LIMITED (JP) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | HCCS, CYP3A7, QPCT | SMN1; SMN2 3385/4885LTA4H 2384/4885HRH3 2960/4885 |
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | MAPKAPK2, MAPKAPK5, MAP4K2 | SMN1; SMN2 3512/4885LTA4H 4045/4885HRH3 1993/4885 |
| US-20060189632-A1 | Pyrazolo[1,5-A] pyrimidine derivatives | MAP3K1, MAP3K5, MAP3K15 | SMN1; SMN2 3775/4885LTA4H 3030/4885HRH3 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.